Drug Profile
Goserelin extended release - Luye Pharma Group
Alternative Names: Baituowei; Goserelin acetate extended release - Luye Pharma Group; Goserelin Acetate Sustained-Release Microspheres for Injection - Luye Pharma Group; Goserelin microspheres for injection - Luye Pharma Group; LY 01005; LY-01022Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Luye Pharma Group
- Class Antineoplastics; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Prostate cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Late-stage disease, Metastatic disease) in China (IM, Controlled release)
- 27 Nov 2023 Luye Pharma Group plans a phase I trial for Breast cancer in China (Luye Pharma Group pipeline, November 2023)
- 12 Sep 2023 Launched for Breast cancer in China (IM)